Showing results (31-40 of 60) with videos related to

Sort By:
Pageof 6
JCO Precision Oncology|March 14, 2024
Investigation of Serum Albumin as a Dynamic Treatment-Specific Surrogate for Outcomes in Patients With Myelofibrosis Treated With RuxolitinibAndrew T Kuykendall, Somedeb Ball, Barbara Mora, et al.
Leukemia Research|December 21, 2022
Clinical characteristics and outcomes of EZH2-mutant myelodysplastic syndrome: A large single institution analysis of 1774 patientsSomedeb Ball, Luis E Aguirre, Akriti G Jain, et al.
American Journal of Hematology|March 5, 2024
SHP2 inhibition displays efficacy as a monotherapy and in combination with JAK2 inhibition in preclinical models of myeloproliferative neoplasmsGarima Pandey, Lucia Mazzacurati, Tegan M Rowsell, et al.
Blood Advances|November 25, 2025
Post-transplant MRD Monitoring by TP53 Duplex Sequencing with APR-246 + Azacitidine Maintenance Predicts OutcomesDavid A Sallman, Amy F McLemore, Rami S Komrokji, et al.
Acta Haematologica|June 15, 2026
Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter studyEdmond Chiche, Caroline Fileni, Sarah Bonnet, et al.
Cancer|September 15, 2022
Molecular annotation of extramedullary acute myeloid leukemia identifies high prevalence of targetable mutationsSomedeb Ball, Todd C Knepper, Yehuda E Deutsch, et al.
The New England Journal of Medicine|February 21, 2024
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia VeraMarina Kremyanskaya, Andrew T Kuykendall, Naveen Pemmaraju, et al.
Leukemia Research|November 8, 2021
MYC overexpression is associated with an early disease progression from MDS to AMLDavid Gajzer, Constantine N Logothetis, David A Sallman, et al.
Medrxiv : the Preprint Server for Health Sciences|July 10, 2026
Hematopoietic mosaic chromosomal alterations are pleiotropic drivers of inflammaging, multimorbidity, and mortalityNicole D Vincelette, Qianxing Mo, Chia-Ho Cheng, et al.
Journal of the American Heart Association|May 6, 2026
Cardiovascular Adverse Events During Venetoclax-Based Treatment in Acute Myeloid LeukemiaSruthi Selvakumar, Sanath Shetty, Alexis Behne Sharma, et al.
Pageof 6